SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Nektar Therapeutics announced that it will be hosting a conference call to discuss today's announcement of a new partnership for NKTR-118 and NKTR-119. The call will begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT).
In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.
Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Nektar Contacts:
SOURCE Nektar Therapeutics
CONTACT: Jennifer Ruddock, Nektar Therapeutics, +1-650-631-4954,
jruddock@nektar.com; Susan Noonan, The SAN Group, +1-212-966-3650,
susan@sanoonan.com
Web site: http://www.nektar.com/
